IDEXX Laboratories, Inc. · NASDAQ (us_market)
Healthcare · Diagnostics & Research · United States
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-02-03$469.04 RISE2025-04-08$361.04 PEAK2025-07-03$547.01 150d | -23.0% 64d | Missed | Missed | — | — | +51.5% 86d | Missed |
DROP2024-03-01$576.87 RISE2024-05-01$468.04 PEAK2024-05-15$548.53 75d | -18.9% 61d | Missed | Missed | — | — | +17.2% 14d | Missed |
DROP2023-07-25$556.67 RISE2023-10-27$391.37 PEAK2024-01-11$558.71 170d | -29.7% 94d | Missed | Missed | — | — | +42.8% 76d | Missed |
DROP2022-08-05$407.78 RISE2022-10-14$324.64 PEAK2023-01-10$469.11 158d | -20.4% 70d | Missed | Missed | — | — | +44.5% 88d | Missed |
DROP2022-04-01$553.44 RISE2022-06-16$327.37 PEAK2022-08-05$407.78 126d | -40.8% 76d | 2022-05-11 $333.90 | 2022-08-02 $398.93 | 57Quality on Sale | 41Watch | +24.6% 50d | +19.5% Held 83d |
DROP2021-12-31$658.46 RISE2022-05-11$333.90 PEAK2022-08-05$407.78 217d | -49.3% 131d | 2022-05-11 $333.90 | 2022-08-02 $398.93 | 57Quality on Sale | 41Watch | +22.1% 86d | +19.5% Duplicate trade Held 83d |
DROP2021-09-23$682.58 RISE2022-01-26$466.52 PEAK2022-04-01$553.44 190d | -31.7% 125d | Missed | Missed | — | — | +18.6% 65d | Missed |
DROP2020-02-19$290.97 RISE2020-03-23$182.94 PEAK2020-06-10$321.89 112d | -37.1% 33d | Missed | Missed | — | — | +76.0% 79d | Missed |
IDEXX Laboratories, Inc. (NASDAQ:IDXX) is one of the best medical technology stocks to buy right now. On May 19, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced that its SDMA kidney biomarker will be built directly into Catalyst CLIPs. Catalyst CLIPs is the most widely used point-of-care chemistry profiles on the company’s Catalyst platform. IDEXX said this integration […]
Although IDEXX Laboratories has lagged the broader market over the past year, Wall Street analysts remain fairly bullish about the company’s long-term growth prospects.
Although IDEXX Laboratories has lagged the broader market over the past year, Wall Street analysts remain fairly bullish about the company’s long-term growth prospects.
WESTBROOK, Maine, May 26, 2026--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.
Earlier in 2026, IDEXX Laboratories integrated SDMA, a key renal biomarker recognized by the International Renal Interest Society, into its widely used Catalyst in-clinic chemistry profiles in the US and Canada to support earlier detection of kidney disease in pets. This move effectively turns routine point-of-care blood testing into an advanced kidney assessment tool, potentially increasing test utilization while keeping veterinary workflows unchanged. We’ll now examine how embedding SDMA...
Earlier in 2026, IDEXX Laboratories integrated SDMA, a key renal biomarker recognized by the International Renal Interest Society, into its widely used Catalyst in-clinic chemistry profiles in the US and Canada to support earlier detection of kidney disease in pets. This move effectively turns routine point-of-care blood testing into an advanced kidney assessment tool, potentially increasing test utilization while keeping veterinary workflows unchanged. We’ll now examine how embedding SDMA...
WESTBROOK, Maine, May 19, 2026--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
WESTBROOK, Maine, May 14, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 27, 2026 from 10:55 am – 11:25 am (ET).
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Asset Fund”. A copy of the letter is available to download here. U.S. equity markets started the year on a positive note. In February, market dynamics changed due to concerns about AI disruption, accelerated by U.S. and Israeli military action in […]
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Asset Fund”. A copy of the letter is available to download here. U.S. equity markets started the year on a positive note. In February, market dynamics changed due to concerns about AI disruption, accelerated by U.S. and Israeli military action in […]
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. IDEXX Laboratories, Inc. is one of the best cancer stocks. TheFly reported on May 5 that IDXX saw its valuation outlook reduced as BofA Securities lowered its price target to $660 from $790 while maintaining a Neutral stance […]
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. IDEXX Laboratories, Inc. is one of the best cancer stocks. TheFly reported on May 5 that IDXX saw its valuation outlook reduced as BofA Securities lowered its price target to $660 from $790 while maintaining a Neutral stance […]
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.
Boston Scientific Corporation outlook: EP share loss vs PFA leadership, Watchman & neuromod growth, improving margins and low valuation. Click for more on BSX.
It's been a good week for IDEXX Laboratories, Inc. ( NASDAQ:IDXX ) shareholders, because the company has just released...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| IDXX | -0.69% | -11.49% | -16.70% | +9.77% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.66% | -5.78% | -13.26% | -2.92% |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-14 | Britt Irene Chang | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | Britt Irene Chang | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-14 | Claflin Bruce L. | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | Claflin Bruce L. | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-14 | ESSIG STUART | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | ESSIG STUART | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-14 | HOOLEY JOSEPH L | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | HOOLEY JOSEPH L | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-14 | JUNIUS DANIEL M | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | JUNIUS DANIEL M | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-14 | Kingsley Lawrence D | Director | A Grant / award(deriv) | 75 | — | +$0 |
| 2026-05-14 | Kingsley Lawrence D | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | Kingsley Lawrence D | Director | A Grant / award(deriv) | 168 | — | +$0 |
| 2026-05-14 | Kingsley Lawrence D | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-14 | Peacock Karen | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | Peacock Karen | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-14 | SAMAD SAM | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | SAMAD SAM | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-14 | Vandebroek Sophie V. | Director | A Grant / award(deriv) | 234 | — | +$0 |
| 2026-05-14 | Vandebroek Sophie V. | Director | A Grant / award(deriv) | 525 | — | +$0 |
| 2026-05-11 | HOOLEY JOSEPH L | Director | M Option exercise(deriv) | 158 | — | — |
| 2026-05-11 | HOOLEY JOSEPH L | Director | M Option exercise | 158 | — | +$0 |
| 2026-05-11 | JUNIUS DANIEL M | Director | M Option exercise(deriv) | 257 | — | — |
| 2026-05-11 | JUNIUS DANIEL M | Director | M Option exercise | 257 | — | +$0 |
| 2026-05-11 | Kingsley Lawrence D | Director | M Option exercise(deriv) | 82 | — | — |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-03upcoming | 3.94 | — | — |
| 2026-05-05 | 3.41 | 3.47 | +1.74% |
| 2026-02-02 | 2.94 | 3.08 | +4.81% |
| 2025-11-03 | 3.15 | 3.40 | +8.08% |
| 2025-08-04 | 3.30 | 3.63 | +9.97% |
| 2025-05-01 | 2.84 | 2.96 | +4.07% |
| 2025-02-03 | 2.40 | 2.62 | +9.21% |
| 2024-10-31 | 2.69 | 2.80 | +4.26% |
| 2024-08-06 | 2.87 | 3.02 | +5.20% |
| 2024-05-01 | 2.68 | 2.81 | +4.79% |
| 2024-02-05 | 2.12 | 2.32 | +9.39% |
| 2023-11-01 | 2.37 | 2.53 | +6.73% |
| 2023-08-01 | 2.47 | 2.67 | +8.15% |
| 2023-05-02 | 2.43 | 2.55 | +4.88% |
| 2023-02-06 | 1.92 | 2.05 | +6.54% |
| 2022-11-01 | 2.04 | 2.15 | +5.52% |